A Phase 1 interventional study of MK-6552 and Placebo in Narcolepsy, sponsored by Merck Sharp & Dohme LLC. Terminated at 5 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-04-14.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 85 studies in Narcolepsy with a site in United States — 19 open to participants now, 20 under way, 8 of them phase 3. Narcolepsy · United States.
Among the 85 studies in Narcolepsy with a site in United States, this one is the 65th largest by enrollment of the 69 interventional ones that give a count, is one of 7 that started in 2024, is one of 13 in phase 1, and was the 61st registered.
158 studies on the registry are indexed under Narcolepsy; 38 are open to participants now.
Browse Narcolepsy studies →19 of the 85 studies in Narcolepsy with a site in United States are open now. Recruiting first, the newest first:
Suven Life Sciences Limited · Sites in United States
Ages 18+
Jazz Pharmaceuticals · Sites in United States
Ages 18–75
University of Utah · Sites in United States
Ages 18+
Takeda · Sites in United States, Australia, China and 4 more countries
Ages 18–70
Harmony Biosciences Management, Inc. · Sites in United States, Belgium, Canada and 4 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 30 Narcolepsy studies recruiting now, 12 (40%) set no upper age limit and 16 (53%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
85 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 24 · Phase 3 24 · Phase 4 3
First in 1996; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 9 is below the median of 78 across 114 interventional studies indexed under Narcolepsy.
Median enrollment 93 across the 69 interventional studies, 191 across the 15 observational. Of the 62 that completed or were terminated, 30 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
66 of 85 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Merck & Co., Inc has 3 studies filed under Narcolepsy — fewer than ten, so there is no comparison to draw.
11 of the studies in Narcolepsy with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07363720Phase 3TakedaA Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy | 2026-12-17 |
| NCT07455383Phase 3Alkermes, Inc.A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 | 2027-05 |
| NCT07598708Phase 3Centessa Pharmaceuticals (UK) LimitedA Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence | 2027-09-30 |
| NCT07675135Phase 3Harmony Biosciences Management, Inc.A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Narcolepsy | 2027-10 |
| NCT07540364Phase 3Suven Life Sciences LimitedA Phase 3 Study to Evaluate the Efficacy and Safety of Samelisant in Patients With Narcolepsy (AWAKE) | 2027-11-19 |
Add all 11 to your calendar (.ics) → With an account.
Among the 85 studies in Narcolepsy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of MK-6552 in participants with Narcolepsy Type 1 (NT1). The effect of single MK-6552 doses were assessed initially under open-label conditions to evaluate the safety, tolerability, and PK of MK-6552. The effect of repeated MK-6552 doses (every 8 hours [q8h] for 7 days) were assessed under double-blind and placebo-controlled conditions.
The study was terminated by the Sponsor on 15OCT2024 out of an abundance of caution regarding elevations in liver function tests in 3 participants (all cases were asymptomatic and none met Hy's law for drug-induced liver injury or SAE criteria).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive single oral doses of MK-6552 in ascending fashion approximately 6 hours apart for a single day, based on safety and tolerability of the previous dose. Then, participants will receive multiple days of MK-6552 dosing (7 consecutive days) at the highest safe and well tolerated MK-6552 dose determined on an individual basis from Part 1.
Drug: MK-6552 · Drug: Placebo
Panel B will assess the effects of repeated MK-6552 dosing across a range of doses compared with placebo.
Drug: MK-6552 · Drug: Placebo
Oral capsule
Oral capsule matched to MK-6552
Number of Participants Experiencing an Adverse Event (AE)
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Events are reported according to dose. The number of participants with ≥1 AE is reported.
Time frame: Up to ~34 weeks
Number of Participants Discontinuing Study Intervention Due to AE
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Events are reported according to dose. The number of participants that discontinued study intervention due to AE(s) is reported.
Time frame: Up to ~34 weeks
Sleep Onset Latency Measured by the Maintenance of Wakefulness Test (MWT) Following 7 Days of MK-6554 Treatment
The MWT is a daytime polysomnographic procedure that measures objectively the ability to remain awake during sleep-inducing circumstances. Sleep onset latency is defined as the first occurrence of sustained sleep (i.e. 3 consecutive 30 second epochs of N1 \[stage 1\] sleep or any single 30 second epoch of N2 \[stage 2\], N3 \[stage 3 and 4 combined\] or REM). The primary outcome measure of sleep onset latency measured by the MWT on Day 7 of daily repeated MK-6552 treatment is reported.
Time frame: 1 hour after Dose 1 and Dose 2 on Day 7
Area Under the Plasma Concentration-Time Curve of MK-6552 From Time Zero to Infinity (AUC0-∞)
The AUC0-∞ of MK-6554 was determined for arms receiving 2 oral doses spaced 6 hours apart.
Time frame: Day 1 Dose 1: Predose, 0.25, 0.5, 1, 2, 3, 4, and 6 hours postdose 1. Day 1 Dose 2: 0.25, 0.5, 1, 2, 3, 4, 6, 8, 18, 21 and 24 hours postdose
Area Under the Plasma Concentration-Time Curve of MK-6552 From Time Zero to 24 Hours Postdose (AUC0-24)
The AUC0-24 of MK-6554 was determined for arms receiving 2 oral doses spaced 6 hours apart.
Time frame: Day 1 Dose 1: Predose, 0.25, 0.5, 1, 2, 3, 4, and 6 hours postdose 1. Day 1 Dose 2: 0.25, 0.5, 1, 2, 3, 4, 6, 8, and 18 hours postdose
Maximum Concentration (Cmax) of MK-6552
The Cmax of MK-6554 was determined for arms receiving 2 oral doses spaced 6 hours apart.
Time frame: Day 1 Dose 1: Predose, 0.25, 0.5, 1, 2, 3, 4, and 6 hours postdose. Day 1 Dose 2: 0.25, 0.5, 1, 2, 3, 4, 6, 8, 18, 21 and 24 hours postdose
Time to Maximum Concentration (Tmax) of MK-6552
The Tmax of MK-6554 was determined for arms receiving 2 oral doses spaced 6 hours apart.
Time frame: Day 1 Dose 1: Predose, 0.25, 0.5, 1, 2, 3, 4, and 6 hours postdose. Day 1 Dose 2: 0.25, 0.5, 1, 2, 3, 4, 6, 8, 18, 21 and 24 hours postdose
Concentration of MK-6522 at 2 Hours Postdose (C2h)
The C2h of MK-6554 was determined for arms receiving 2 oral doses spaced 6 hours apart.
Time frame: Day 1 Dose 1: 2 hours postdose. Day 1 Dose 2: 2 hours postdose.
Concentration of MK-6522 at 6 Hours Postdose (C6h)
The C6h of MK-6554 was determined for arms receiving 2 oral doses spaced 6 hours apart.
Time frame: Day 1 Dose 1: 6 hours postdose
Concentration of MK-6522 at 18 Hours Postdose (C18h)
The C18h of MK-6554 was determined for arms receiving 2 oral doses spaced 6 hours apart.
Time frame: Day 1 Dose 2: 18 hours postdose
Apparent Oral Clearance (CL/F) of MK-6552
The CL/F of MK-6554 was determined for arms receiving 2 oral doses spaced 6 hours apart.
Time frame: Day 1 Dose 1: Predose, 0.25, 0.5, 1, 2, 3, 4, and 6 hours postdose 1. Day 1 Dose 2: 0.25, 0.5, 1, 2, 3, 4, 6, 8, 18, 21 and 24 hours postdose
Apparent Volume of Distribution (Vz/F) of MK-6552
The Vz/F of MK-6554 was determined for arms receiving 2 oral doses spaced 6 hours apart.
Time frame: Day 1 Dose 1: Predose, 0.25, 0.5, 1, 2, 3, 4, and 6 hours postdose 1. Day 1 Dose 2: 0.25, 0.5, 1, 2, 3, 4, 6, 8, 18, 21 and 24 hours postdose
Apparent Terminal Half-life (t½) of MK-6552
The apparent t½ of MK-6554 was determined for arms receiving 2 oral doses spaced 6 hours apart.
Time frame: Day 1 Dose 1: Predose, 0.25, 0.5, 1, 2, 3, 4, and 6 hours postdose. Day 1 Dose 2: 0.25, 0.5, 1, 2, 3, 4, 6, 8, 18, 21 and 24 hours postdose
Adult participants with narcolepsy type 1 were enrolled at 5 study sites in the United States.
| Milestone | Panel A | Panel B |
|---|---|---|
| Started | 9 | 0 |
| Period 1: mk-6552 0.1 mg + 4-day washout | 9 | 0 |
| Period 2: mk-6552 0.25 mg + 4-day washout | 8 | 0 |
| Period 3: mk-6552 0.5 mg + 4-day washout | 7 | 0 |
| Period 4: mk-6552 1 mg + 4-day washout | 8 | 0 |
| Completed | 8 | 0 |
| Not completed | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Milestone | Panel A | Panel B |
|---|---|---|
| Started | 8 | 0 |
| Completed | 7 | 0 |
| Not completed | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Milestone | Panel A | Panel B |
|---|---|---|
| Started | 7 | 0 |
| Mk-6552 1.0 mg x 7 days + 2-day washout | 5 | 0 |
| Placebo x 7 days + 2-day washout | 3 | 0 |
| Completed | 6 | 0 |
| Not completed | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Milestone | Panel A | Panel B |
|---|---|---|
| Started | 6 | 0 |
| Mk-6552 1.0 mg x 7 days + 2-day washout | 1 | 0 |
| Mk-6552 0.1 mg x 7 days + 2-day washout | 1 | 0 |
| Placebo x 7 days + 2-day washout | 4 | 0 |
| Completed | 6 | 0 |
| Not completed | 0 | 0 |
The AUC0-∞ of MK-6554 was determined for arms receiving 2 oral doses spaced 6 hours apart.
| hr*nmol/L | MK-6552 0.1 mg | MK-6552 0.25 mg | MK-6552 0.5 mg | MK-6552 1 mg | MK-6552 1 mg x 7 Days | MK-6552 0.1 mg x 7 Days | Placebo x 7 Days |
|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration-Time Curve of MK-6552 From Time Zero to Infinity (AUC0-∞) | 7.99 (6.22 to 10.3) | 26.2 (20.1 to 34.1) | 51.8 (40.2 to 66.7) | 106 (80.1 to 139) | — | — | — |
The AUC0-24 of MK-6554 was determined for arms receiving 2 oral doses spaced 6 hours apart.
| hr*nmol/L | MK-6552 0.1 mg | MK-6552 0.25 mg | MK-6552 0.5 mg | MK-6552 1 mg | MK-6552 1 mg x 7 Days | MK-6552 0.1 mg x 7 Days | Placebo x 7 Days |
|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration-Time Curve of MK-6552 From Time Zero to 24 Hours Postdose (AUC0-24) | 7.22 (5.93 to 8.79) | 19.8 (16.2 to 24.2) | 41.1 (33.4 to 50.6) | 78.7 (63.4 to 97.7) | — | — | — |
The Cmax of MK-6554 was determined for arms receiving 2 oral doses spaced 6 hours apart.
| nmol/L | MK-6552 0.1 mg | MK-6552 0.25 mg | MK-6552 0.5 mg | MK-6552 1 mg | MK-6552 1 mg x 7 Days | MK-6552 0.1 mg x 7 Days | Placebo x 7 Days |
|---|---|---|---|---|---|---|---|
| Day 1 Dose 1 | 1.35 (1.06 to 1.72) | 3.46 (2.69 to 4.45) | 5.96 (4.58 to 7.77) | 10.0 (7.59 to 13.3) | — | — | — |
| Day 1 Dose 2 | 0.500 (0.366 to 0.684) | 1.34 (0.969 to 1.85) | 3.84 (2.72 to 5.4) | 7.69 (5.13 to 11.5) | — | — | — |
The Tmax of MK-6554 was determined for arms receiving 2 oral doses spaced 6 hours apart.
| hours | MK-6552 0.1 mg | MK-6552 0.25 mg | MK-6552 0.5 mg | MK-6552 1 mg | MK-6552 1 mg x 7 Days | MK-6552 0.1 mg x 7 Days | Placebo x 7 Days |
|---|---|---|---|---|---|---|---|
| Day 1 Dose 1 | 0.52 (0.48 to 2.23) | 0.79 (0.50 to 1.32) | 1.00 (0.50 to 1.47) | 1.03 (0.53 to 2.00) | — | — | — |
| Day 1 Dose 2 | 4.02 (2.55 to 6.33) | 2.53 (0.97 to 8.00) | 2.30 (0.50 to 4.00) | 2.98 (0.98 to 6.05) | — | — | — |
The C2h of MK-6554 was determined for arms receiving 2 oral doses spaced 6 hours apart.
| nmol/L | MK-6552 0.1 mg | MK-6552 0.25 mg | MK-6552 0.5 mg | MK-6552 1 mg | MK-6552 1 mg x 7 Days | MK-6552 0.1 mg x 7 Days | Placebo x 7 Days |
|---|---|---|---|---|---|---|---|
| Day 1 Dose 1 | 0.559 (0.4333 to 0.722) | 1.66 (1.28 to 2.15) | 3.31 (2.54 to 4.33) | 6.68 (5.07 to 8.80) | — | — | — |
| Day 1 Dose 2 | 0.389 (0.277 to 0.546) | 0.997 (0.703 to 1.41) | 3.19 (2.20 to 4.61) | 5.35 (3.49 to 8.19) | — | — | — |
The C6h of MK-6554 was determined for arms receiving 2 oral doses spaced 6 hours apart.
| nmol/L | MK-6552 0.1 mg | MK-6552 0.25 mg | MK-6552 0.5 mg | MK-6552 1 mg | MK-6552 1 mg x 7 Days | MK-6552 0.1 mg x 7 Days | Placebo x 7 Days |
|---|---|---|---|---|---|---|---|
| Concentration of MK-6522 at 6 Hours Postdose (C6h) | 0.171 (0.134 to 0.220) | 0.405 (0.315 to 0.520) | 0.861 (0.667 to 1.11) | 1.81 (1.39 to 2.35) | — | — | — |
The C18h of MK-6554 was determined for arms receiving 2 oral doses spaced 6 hours apart.
| nmol/L | MK-6552 0.1 mg | MK-6552 0.25 mg | MK-6552 0.5 mg | MK-6552 1 mg | MK-6552 1 mg x 7 Days | MK-6552 0.1 mg x 7 Days | Placebo x 7 Days |
|---|---|---|---|---|---|---|---|
| Concentration of MK-6522 at 18 Hours Postdose (C18h) | 0.157 (0.101 to 0.244) | 0.323 (0.223 to 0.467) | 0.617 (0.422 to 0.904) | 1.19 (0.784 to 1.81) | — | — | — |
The CL/F of MK-6554 was determined for arms receiving 2 oral doses spaced 6 hours apart.
| Liters/hour | MK-6552 0.1 mg | MK-6552 0.25 mg | MK-6552 0.5 mg | MK-6552 1 mg | MK-6552 1 mg x 7 Days | MK-6552 0.1 mg x 7 Days | Placebo x 7 Days |
|---|---|---|---|---|---|---|---|
| Apparent Oral Clearance (CL/F) of MK-6552 | 52.3 ± 34.8 | 42.6 ± 32.7 | 43.0 ± 35.1 | 45.0 ± 22.9 | — | — | — |
The Vz/F of MK-6554 was determined for arms receiving 2 oral doses spaced 6 hours apart.
| Liters | MK-6552 0.1 mg | MK-6552 0.25 mg | MK-6552 0.5 mg | MK-6552 1 mg | MK-6552 1 mg x 7 Days | MK-6552 0.1 mg x 7 Days | Placebo x 7 Days |
|---|---|---|---|---|---|---|---|
| Apparent Volume of Distribution (Vz/F) of MK-6552 | 376.4 ± 39.6 | 489.2 ± 21.5 | 608.9 ± 32.5 | 546.7 ± 17.1 | — | — | — |
The apparent t½ of MK-6554 was determined for arms receiving 2 oral doses spaced 6 hours apart.
| hours | MK-6552 0.1 mg | MK-6552 0.25 mg | MK-6552 0.5 mg | MK-6552 1 mg | MK-6552 1 mg x 7 Days | MK-6552 0.1 mg x 7 Days | Placebo x 7 Days |
|---|---|---|---|---|---|---|---|
| Apparent Terminal Half-life (t½) of MK-6552 | 5.0 ± 71.8 | 8.0 ± 40.5 | 9.8 ± 21.9 | 8.4 ± 24.7 | — | — | — |
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Events are reported according to dose. The number of participants with ≥1 AE is reported.
| Participants | MK-6552 0.1 mg | MK-6552 0.25 mg | MK-6552 0.5 mg | MK-6552 1 mg | MK-6552 1 mg x 7 Days | MK-6552 0.1 mg x 7 Days | Placebo x 7 Days |
|---|---|---|---|---|---|---|---|
| Number of Participants Experiencing an Adverse Event (AE) | 3 | 2 | 1 | 1 | 2 | 0 | 1 |
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Events are reported according to dose. The number of participants that discontinued study intervention due to AE(s) is reported.
| Participants | MK-6552 0.1 mg | MK-6552 0.25 mg | MK-6552 0.5 mg | MK-6552 1 mg | MK-6552 1 mg x 7 Days | MK-6552 0.1 mg x 7 Days | Placebo x 7 Days |
|---|---|---|---|---|---|---|---|
| Number of Participants Discontinuing Study Intervention Due to AE | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The MWT is a daytime polysomnographic procedure that measures objectively the ability to remain awake during sleep-inducing circumstances. Sleep onset latency is defined as the first occurrence of sustained sleep (i.e. 3 consecutive 30 second epochs of N1 \[stage 1\] sleep or any single 30 second epoch of N2 \[stage 2\], N3 \[stage 3 and 4 combined\] or REM). The primary outcome measure of sleep onset latency measured by the MWT on Day 7 of daily repeated MK-6552 treatment is reported.
| minutes | MK-6552 0.1 mg | MK-6552 0.25 mg | MK-6552 0.5 mg | MK-6552 1 mg | MK-6552 1 mg x 7 Days | MK-6552 0.1 mg x 7 Days | Placebo x 7 Days |
|---|---|---|---|---|---|---|---|
| 1 Hour after Dose 1 | — | — | — | — | 18.63 (0.00 to 40.00) | 8.50 (NA to NA) | 10.30 (0.00 to 21.82) |
| 1 Hour after Dose 2 | — | — | — | — | 29.80 (8.92 to 40.00) | 40.00 (NA to NA) | 12.19 (0.00 to 27.95) |
Collected over Up to ~34 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MK-6552 0.1 mg | 3/9 (33.3%) | 0/9 (0%) | 3/9 (33.3%) |
| MK-6552 0.25 mg | 2/8 (25%) | 0/8 (0%) | 2/8 (25%) |
| MK-6552 0.5 mg | 1/7 (14.3%) | 0/7 (0%) | 1/7 (14.3%) |
| MK-6552 1 mg | 1/7 (14.3%) | 0/7 (0%) | 1/7 (14.3%) |
| MK-6552 1 mg x 7 Days | 2/6 (33.3%) | 0/6 (0%) | 2/6 (33.3%) |
| MK-6552 0.1 mg x 7 Days | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Placebo x 7 Days | 1/7 (14.3%) | 0/7 (0%) | 1/7 (14.3%) |
| Event | MK-6552 0.1 mg | MK-6552 0.25 mg | MK-6552 0.5 mg | MK-6552 1 mg | MK-6552 1 mg x 7 Days | MK-6552 0.1 mg x 7 Days | Placebo x 7 Days |
|---|---|---|---|---|---|---|---|
| Conjunctival hyperaemiaEye disorders | 0/9 | 0/8 | 0/7 | 0/7 | 1/6 | 0/1 | 0/7 |
| NauseaGastrointestinal disorders | 0/9 | 0/8 | 0/7 | 1/7 | 1/6 | 0/1 | 0/7 |
| MigraineNervous system disorders | 0/9 | 0/8 | 0/7 | 0/7 | 1/6 | 0/1 | 1/7 |
| Back painMusculoskeletal and connective tissue disorders | 0/9 | 0/8 | 1/7 | 0/7 | 0/6 | 0/1 | 0/7 |
| Neck painMusculoskeletal and connective tissue disorders | 0/9 | 0/8 | 1/7 | 0/7 | 0/6 | 0/1 | 0/7 |
| DizzinessNervous system disorders | 1/9 | 1/8 | 0/7 | 1/7 | 0/6 | 0/1 | 0/7 |
| HeadacheNervous system disorders | 0/9 | 1/8 | 0/7 | 0/7 | 0/6 | 0/1 | 1/7 |
| InsomniaPsychiatric disorders | 1/9 | 1/8 | 0/7 | 0/7 | 0/6 | 0/1 | 0/7 |
| Orthostatic hypotensionVascular disorders | 1/9 | 1/8 | 0/7 | 0/7 | 0/6 | 0/1 | 0/7 |
| Feeling abnormalGeneral disorders | 1/9 | 0/8 | 0/7 | 0/7 | 0/6 | 0/1 | 0/7 |
| Age, Continuous(years) | Panel A |
|---|---|
| Mean | 33.7 ± 12.6 |
| Sex: Female, Male(Participants) | Panel A |
|---|---|
| Female | 6 |
| Male | 3 |
| Ethnicity (NIH/OMB)(Participants) | Panel A |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 7 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Panel A |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 3 |
| White | 5 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Jan 2024 to primary completion in Oct 2024, 8 months.
Results were first posted in Apr 2026, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MK-6552